vs
Side-by-side financial comparison of CF BANKSHARES INC. (CFBK) and Cue Biopharma, Inc. (CUE). Click either name above to swap in a different company.
Cue Biopharma, Inc. is the larger business by last-quarter revenue ($21.9M vs $15.7M, roughly 1.4× CF BANKSHARES INC.). CF BANKSHARES INC. runs the higher net margin — 40.0% vs 7.2%, a 32.8% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 12.6%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 13.7%).
CF Bankshares Inc. is a U.S.-based regional bank holding company operating through its community bank subsidiary. It offers a full suite of personal and commercial banking solutions including deposit products, various loan options, wealth management services and digital banking tools, primarily serving individual consumers and small-to-medium business clients across the U.S. Midwest region.
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
CFBK vs CUE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.7M | $21.9M |
| Net Profit | $5.7M | $1.6M |
| Gross Margin | — | — |
| Operating Margin | 43.4% | 9.0% |
| Net Margin | 40.0% | 7.2% |
| Revenue YoY | 12.6% | 1292.3% |
| Net Profit YoY | 29.9% | 116.7% |
| EPS (diluted) | $0.88 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.7M | $21.9M | ||
| Q3 25 | $15.5M | $2.1M | ||
| Q2 25 | $15.6M | $3.0M | ||
| Q1 25 | $14.1M | $421.0K | ||
| Q4 24 | $14.0M | $1.6M | ||
| Q3 24 | $13.1M | $3.3M | ||
| Q2 24 | $12.6M | $2.7M | ||
| Q1 24 | $12.2M | $1.7M |
| Q4 25 | $5.7M | $1.6M | ||
| Q3 25 | $2.3M | $-7.4M | ||
| Q2 25 | $5.0M | $-8.5M | ||
| Q1 25 | $4.4M | $-12.3M | ||
| Q4 24 | $4.4M | — | ||
| Q3 24 | $4.2M | $-8.7M | ||
| Q2 24 | $1.7M | $-10.2M | ||
| Q1 24 | $3.1M | $-12.3M |
| Q4 25 | 43.4% | 9.0% | ||
| Q3 25 | 17.5% | -353.4% | ||
| Q2 25 | 41.1% | -292.3% | ||
| Q1 25 | 39.5% | -2921.4% | ||
| Q4 24 | 36.9% | — | ||
| Q3 24 | 40.4% | -264.2% | ||
| Q2 24 | 15.4% | -390.6% | ||
| Q1 24 | 30.9% | -737.8% |
| Q4 25 | 40.0% | 7.2% | ||
| Q3 25 | 15.1% | -346.6% | ||
| Q2 25 | 32.3% | -287.1% | ||
| Q1 25 | 31.4% | -2911.4% | ||
| Q4 24 | 35.2% | — | ||
| Q3 24 | 32.2% | -259.6% | ||
| Q2 24 | 13.5% | -382.7% | ||
| Q1 24 | 25.2% | -719.1% |
| Q4 25 | $0.88 | $0.05 | ||
| Q3 25 | $0.36 | $-0.07 | ||
| Q2 25 | $0.77 | $-0.09 | ||
| Q1 25 | $0.68 | $-0.17 | ||
| Q4 24 | $0.68 | — | ||
| Q3 24 | $0.65 | $-0.17 | ||
| Q2 24 | $0.26 | $-0.20 | ||
| Q1 24 | $0.47 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $259.0M | $27.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $184.4M | $26.4M |
| Total Assets | $2.1B | $42.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $259.0M | $27.1M | ||
| Q3 25 | $272.4M | $11.7M | ||
| Q2 25 | $275.7M | $27.5M | ||
| Q1 25 | $241.0M | $13.1M | ||
| Q4 24 | $235.3M | $22.5M | ||
| Q3 24 | $233.5M | $32.4M | ||
| Q2 24 | $241.8M | $30.0M | ||
| Q1 24 | $236.9M | $41.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $1.0M | ||
| Q2 24 | — | $2.0M | ||
| Q1 24 | — | $3.0M |
| Q4 25 | $184.4M | $26.4M | ||
| Q3 25 | $179.3M | $13.2M | ||
| Q2 25 | $177.0M | $18.2M | ||
| Q1 25 | $172.7M | $6.6M | ||
| Q4 24 | $168.4M | $17.5M | ||
| Q3 24 | $164.0M | $25.4M | ||
| Q2 24 | $159.6M | $21.6M | ||
| Q1 24 | $158.0M | $30.0M |
| Q4 25 | $2.1B | $42.2M | ||
| Q3 25 | $2.1B | $31.6M | ||
| Q2 25 | $2.1B | $40.7M | ||
| Q1 25 | $2.1B | $22.3M | ||
| Q4 24 | $2.1B | $32.2M | ||
| Q3 24 | $2.1B | $44.8M | ||
| Q2 24 | $2.0B | $42.3M | ||
| Q1 24 | $2.0B | $54.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.09× | ||
| Q1 24 | — | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.7M | $-1.1M |
| Free Cash FlowOCF − Capex | $18.2M | — |
| FCF MarginFCF / Revenue | 115.6% | — |
| Capex IntensityCapex / Revenue | 3.1% | 0.0% |
| Cash ConversionOCF / Net Profit | 3.26× | -0.68× |
| TTM Free Cash FlowTrailing 4 quarters | $33.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.7M | $-1.1M | ||
| Q3 25 | $5.5M | $-9.0M | ||
| Q2 25 | $8.0M | $-3.4M | ||
| Q1 25 | $2.2M | $-8.2M | ||
| Q4 24 | $14.2M | $-36.3M | ||
| Q3 24 | $-1.3M | $-7.5M | ||
| Q2 24 | $4.0M | $-10.0M | ||
| Q1 24 | $-1.2M | $-9.8M |
| Q4 25 | $18.2M | — | ||
| Q3 25 | $5.2M | — | ||
| Q2 25 | $7.8M | $-3.4M | ||
| Q1 25 | $2.2M | $-8.3M | ||
| Q4 24 | $13.9M | $-36.4M | ||
| Q3 24 | $-1.3M | $-7.5M | ||
| Q2 24 | $4.0M | $-10.0M | ||
| Q1 24 | $-1.2M | $-9.8M |
| Q4 25 | 115.6% | — | ||
| Q3 25 | 33.6% | — | ||
| Q2 25 | 50.3% | -116.5% | ||
| Q1 25 | 15.2% | -1976.7% | ||
| Q4 24 | 99.6% | -2309.3% | ||
| Q3 24 | -9.9% | -225.7% | ||
| Q2 24 | 31.6% | -376.2% | ||
| Q1 24 | -9.5% | -573.0% |
| Q4 25 | 3.1% | 0.0% | ||
| Q3 25 | 1.7% | 0.0% | ||
| Q2 25 | 0.7% | 0.9% | ||
| Q1 25 | 0.4% | 35.6% | ||
| Q4 24 | 1.9% | 4.2% | ||
| Q3 24 | 0.2% | 0.0% | ||
| Q2 24 | 0.1% | 0.4% | ||
| Q1 24 | 0.0% | 3.2% |
| Q4 25 | 3.26× | -0.68× | ||
| Q3 25 | 2.34× | — | ||
| Q2 25 | 1.58× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 3.21× | — | ||
| Q3 24 | -0.30× | — | ||
| Q2 24 | 2.35× | — | ||
| Q1 24 | -0.38× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CFBK
Segment breakdown not available.
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
